Tag:

Valeant

Latest Headlines

Latest Headlines

Valeant temporarily swears off dealmaking to cut debt--and prove it's not desperate

After serial acquirer Valeant lost a months-long takeover battle for Allergan, many industry-watchers expected the company to restore its dealmaking reputation with another quick pickup. But the Canadian pharma may be heading in the opposite direction.

Actavis cuts 200 U.S jobs, perhaps providing a glimpse of what is in store at Allergan

California's Allergan desperately wanted to avoid a hostile takeover by Valeant, fearful it would ravage its R&D operations in favor of its marketing oriented approach to the business. So it turned to Actavis as a white knight. But Actavis is also known to cut jobs with impunity to make deals pay and Allergan need look only a few miles down the road for proof of that as Actavis prepares to lay off 200 at it operations in Corona, CA.

Valeant CEO touts R&D output with new dermatology approval

Less than two weeks after losing longtime acquisition target Allergan--which happily sold itself to Actavis to dodge Valeant's hostile bid and the R&D cuts it feared would come along with it--the Canadian pharma is talking up the productivity of its own labs.

UPDATED: Has Allergan failure weakened Valeant CEO's M&A hand?

Valeant CEO J. Michael Pearson upheld his reputation as a disciplined bidder when he refused to top Actavis' $66 billion bid for Allergan. But now that his company has nothing to show for the past 7 months, has its dealmaking reputation taken a hit?

Actavis' merger cost-cutting isn't Valeant-style. But it's still $1.8B

With the excitement over Actavis' white-knight swoop-in for Allergan out of the way, it's time to take a closer look at the transaction--and how it compares with Valeant's proposed Allergan tie-up.

Valeant and Allergan's wining-and-dining shows docs still hold the script reins

Payers have been grabbing more and more of the spotlight as script gatekeepers lately. But if the recently concluded takeover fight between Valeant and Allergan is any indication, doctors are still extremely influential--and can be influenced.

Actavis ready to leap into Big Pharma with $64B bid for Allergan

A months-long pursuit of Allergan may be about to come to a close for Valeant and activist investor Bill Ackman--but not with the results they were hoping for.

Actavis ready to thwart Valeant with $60B-plus Allergan buyout: Bloomberg

Heads up, Valeant. Actavis is reportedly in talks to snatch up Allergan--and word is it could happen quickly.

WSJ: Pfizer spinoff Zoetis might be Valeant's backup plan if Allergan bid fails

Rumor has it, thanks to potential white knight Actavis, Bill Ackman and Valeant face a serious threat to their Allergan hostile bid. But Ackman may already be preparing for another move.

Plant power outage zaps the juice from AMRI's earnings

Earlier this year, AMRI paid $110 million for injectable drug specialist Oso Biopharmaceuticals Manufacturing, expecting to make some extra money in its contract manufacturing operations. Instead, a power loss at that company's facility in New Mexico was a big factor in it reporting a loss in the last quarter.